Epidemiological studies of bioprosthetic aortic valves
Author: Dismorr, Michael
Date: 2022-11-18
Location: Inghesalen, Widerströmska huset, Tomtebodavägen 18, Karolinska Institutet, Solna
Time: 09.00
Department: Inst för molekylär medicin och kirurgi / Dept of Molecular Medicine and Surgery
View/ Open:
Thesis (21.96Mb)
Abstract
Background: The use of bioprosthetic valves is common and offers a prosthetic option that does not require anti-coagulant therapy, but with shorter valve longevity compared to mechanical prostheses. Valve model selection might influence the long-term performance of the prosthesis. The research questions in the four studies were 1) Does blood type A-like antigens on porcine valves lead to decreased long-term performance of the valve in blood type B/0 patients, 2) Is there a difference in long-term performance between bovine and porcine valves, 3) Does some aortic valve models perform better or worse compared to other aortic valve models, 4) Does prosthesis-patient mismatch (PPM) impact long-term survival, valve reintervention and heart failure hospitalization.
Methods and results: Study I. Patients who received a porcine valve between 1995 and 2012 were identified from the Swedish cardiac surgery register and categorized according to blood type B/0 (1693, 49.5%) and A/AB (1724, 50.5%). The groups had similar baseline characteristics. The cumulative incidence of valve reintervention at 15 years was 3.4% (95% CI: 2.5 to 4.4%) and 3.6% (95% CI: 2.6 to 4.6%) in the B/0 and A/AB groups, respectively. After multivariable adjustment, there was no difference in valve reintervention (HR 0.95, 95% CI: 0.62 to 1.45), heart failure hospitalization (HR 0.92, 95% CI: 0.77 to 1.08) and all-cause mortality (HR 0.95, 95% CI: 0.87 to 1.05) rates in patients with blood type B/0 compared to patients with blood type A/AB. Study II. Patients who received a porcine (4194, 33%) or bovine (8647, 67%) aortic valve between 1995 and 2012 were identified from the Swedish cardiac surgery register. Inverse probability of treatment weighting was used to adjust for inter-group differences. Porcine valves were associated with improved survival (HR 0.90, 95% CI: 0.85 to 0.96) and an increased risk for valve reintervention (HR 1.48, 95% CI: 1.11 to 1.98). There was no difference in heart failure hospitalization between porcine and bovine valves. Study III. All patients who underwent primary surgical bioprosthetic aortic valve replacement in Sweden 2003 to 2018 were identified from the Swedish cardiac surgery register. Patients were categorized according to valve model; Perimount, Mosaic/Hancock, Biocor/Epic, Mitroflow/Crown, Soprano and Trifecta. Regression standardization was used to account for differences in baseline characteristics. Perimount had the lowest, and Mitroflow/Crown had the highest cumulative incidence of reintervention (3.6%, 95% CI: 3.1 to 4.2% and 12%, 95% CI: 9.8 to 15%), all-cause mortality (44%, 95% CI: 43 to 45% and 54%, 95% CI: 52 to 57%) and heart failure hospitalization (13%, 95% CI: 12 to 14% and 20%, 95% CI: 18 to 23%) at ten years, respectively. Study IV. All patients who underwent primary surgical bioprosthetic aortic valve replacement in Sweden 2003 to 2018 were identified from the Swedish cardiac surgery register. Patients were categorized according to no (7377, 45%), moderate (8502, 52%) and severe (544, 3%) PPM, estimated by valve model, valve size and the patient’s body surface area. The survival difference at ten years was 4.6% (95% CI: 0.7 to 8.5%) and 1.7% (95% CI: 0.1 to 3.3%) between no versus severe and moderate PPM, respectively. Severe PPM was also associated with a significant increase in heart failure hospitalization, with a ten-year difference of 6.0% (95% CI: 2.2 to 9.7%) compared to no PPM. There was no difference in valve reintervention between different grades of PPM.
Conclusions: 1) It is safe to use porcine valves irrespective of blood type, 2) Porcine valves increases the risk for subsequent valve interventions, 3) The widespread use of the Perimount valve is supported by excellent long-term clinical performance, and an increased clinical vigilance is warranted in patients with a Mitroflow/Crown or Soprano valve, 4) Steps should be taken to avoid severe PPM, but the clinical effect of moderate PPM might be negligible.
Methods and results: Study I. Patients who received a porcine valve between 1995 and 2012 were identified from the Swedish cardiac surgery register and categorized according to blood type B/0 (1693, 49.5%) and A/AB (1724, 50.5%). The groups had similar baseline characteristics. The cumulative incidence of valve reintervention at 15 years was 3.4% (95% CI: 2.5 to 4.4%) and 3.6% (95% CI: 2.6 to 4.6%) in the B/0 and A/AB groups, respectively. After multivariable adjustment, there was no difference in valve reintervention (HR 0.95, 95% CI: 0.62 to 1.45), heart failure hospitalization (HR 0.92, 95% CI: 0.77 to 1.08) and all-cause mortality (HR 0.95, 95% CI: 0.87 to 1.05) rates in patients with blood type B/0 compared to patients with blood type A/AB. Study II. Patients who received a porcine (4194, 33%) or bovine (8647, 67%) aortic valve between 1995 and 2012 were identified from the Swedish cardiac surgery register. Inverse probability of treatment weighting was used to adjust for inter-group differences. Porcine valves were associated with improved survival (HR 0.90, 95% CI: 0.85 to 0.96) and an increased risk for valve reintervention (HR 1.48, 95% CI: 1.11 to 1.98). There was no difference in heart failure hospitalization between porcine and bovine valves. Study III. All patients who underwent primary surgical bioprosthetic aortic valve replacement in Sweden 2003 to 2018 were identified from the Swedish cardiac surgery register. Patients were categorized according to valve model; Perimount, Mosaic/Hancock, Biocor/Epic, Mitroflow/Crown, Soprano and Trifecta. Regression standardization was used to account for differences in baseline characteristics. Perimount had the lowest, and Mitroflow/Crown had the highest cumulative incidence of reintervention (3.6%, 95% CI: 3.1 to 4.2% and 12%, 95% CI: 9.8 to 15%), all-cause mortality (44%, 95% CI: 43 to 45% and 54%, 95% CI: 52 to 57%) and heart failure hospitalization (13%, 95% CI: 12 to 14% and 20%, 95% CI: 18 to 23%) at ten years, respectively. Study IV. All patients who underwent primary surgical bioprosthetic aortic valve replacement in Sweden 2003 to 2018 were identified from the Swedish cardiac surgery register. Patients were categorized according to no (7377, 45%), moderate (8502, 52%) and severe (544, 3%) PPM, estimated by valve model, valve size and the patient’s body surface area. The survival difference at ten years was 4.6% (95% CI: 0.7 to 8.5%) and 1.7% (95% CI: 0.1 to 3.3%) between no versus severe and moderate PPM, respectively. Severe PPM was also associated with a significant increase in heart failure hospitalization, with a ten-year difference of 6.0% (95% CI: 2.2 to 9.7%) compared to no PPM. There was no difference in valve reintervention between different grades of PPM.
Conclusions: 1) It is safe to use porcine valves irrespective of blood type, 2) Porcine valves increases the risk for subsequent valve interventions, 3) The widespread use of the Perimount valve is supported by excellent long-term clinical performance, and an increased clinical vigilance is warranted in patients with a Mitroflow/Crown or Soprano valve, 4) Steps should be taken to avoid severe PPM, but the clinical effect of moderate PPM might be negligible.
List of papers:
I. Michael Persson, Gustaf Edgren, Magnus Dalén, Natalie Glaser, Martin L Olsson, Anders Franco-Cereceda, Martin J Holzmann, Ulrik Sartipy. ABO blood type and risk of porcine bioprosthetic aortic valve degeneration: SWEDEHEART observational cohort study. BMJ Open. 2019;9(5):e029109.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Michael Persson, Natalie Glaser, Anders Franco-Cereceda, Johan Nilsson, Martin J Holzmann, Ulrik Sartipy. Porcine vs Bovine Bioprosthetic Aortic Valves: Long-Term Clinical Results. Ann Thorac Surg. 2021;111:529-36
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Michael Persson, Natalie Glaser, Johan Nilsson, Örjan Friberg, Anders Franco-Cereceda, Ulrik Sartipy. Comparison of Long-term Performance of Bioprosthetic Aortic Valves in Sweden From 2003 to 2018. JAMA Netw Open. 2022;5(3):e220962
Fulltext (DOI)
Pubmed
View record in Web of Science®
IV. Michael Dismorr, Natalie Glaser, Anders Franco-Cereceda, Ulrik Sartipy. The Effect of Prosthesis-Patient Mismatch on Long-term Clinical Outcomes After Bioprosthetic Aortic Valve Replacement. [Manuscript]
I. Michael Persson, Gustaf Edgren, Magnus Dalén, Natalie Glaser, Martin L Olsson, Anders Franco-Cereceda, Martin J Holzmann, Ulrik Sartipy. ABO blood type and risk of porcine bioprosthetic aortic valve degeneration: SWEDEHEART observational cohort study. BMJ Open. 2019;9(5):e029109.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Michael Persson, Natalie Glaser, Anders Franco-Cereceda, Johan Nilsson, Martin J Holzmann, Ulrik Sartipy. Porcine vs Bovine Bioprosthetic Aortic Valves: Long-Term Clinical Results. Ann Thorac Surg. 2021;111:529-36
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Michael Persson, Natalie Glaser, Johan Nilsson, Örjan Friberg, Anders Franco-Cereceda, Ulrik Sartipy. Comparison of Long-term Performance of Bioprosthetic Aortic Valves in Sweden From 2003 to 2018. JAMA Netw Open. 2022;5(3):e220962
Fulltext (DOI)
Pubmed
View record in Web of Science®
IV. Michael Dismorr, Natalie Glaser, Anders Franco-Cereceda, Ulrik Sartipy. The Effect of Prosthesis-Patient Mismatch on Long-term Clinical Outcomes After Bioprosthetic Aortic Valve Replacement. [Manuscript]
Institution: Karolinska Institutet
Supervisor: Sartipy, Ulrik
Co-supervisor: Glaser, Natalie; Franco-Cereceda, Anders
Issue date: 2022-09-27
Rights:
Publication year: 2022
ISBN: 978-91-8016-738-3
Statistics
Total Visits
Views | |
---|---|
Epidemiological ... | 525 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
Epidemiological ... | 23 | 20 | 24 | 12 | 6 | 12 | 13 |
File Visits
Views | |
---|---|
Thesis_Michael_Dismorr.pdf | 142 |
Final_thesis.pdf | 2 |
Top country views
Views | |
---|---|
United States | 144 |
Sweden | 120 |
Ireland | 48 |
Germany | 34 |
United Kingdom | 14 |
China | 11 |
Chile | 10 |
Denmark | 8 |
Austria | 7 |
Canada | 7 |
Top cities views
Views | |
---|---|
Dublin | 45 |
Scottsdale | 24 |
Stockholm | 22 |
Mountain View | 14 |
Ashburn | 13 |
Malmo | 8 |
Santiago | 8 |
Robstown | 6 |
Bromma | 5 |
Paris | 5 |